Tempramed expands distribution partnership in S. Korea

Executive Summary

• Tempramed Technologies Ltd. has secured a new commercial order and expanded its distribution partnership with Mavericks Co. Ltd. in South Korea.
• The expansion leverages Tempramed's recently granted South Korean patent for its proprietary thermal insulation technology and aims to accelerate market penetration in one of Asia's fastest-growing markets for injectable therapies.
• The agreement strengthens Tempramed's global footprint, building on recent distribution deals in Turkey, Israel, and Europe, while addressing the rising demand for temperature-sensitive medications like insulin and GLP-1 agonists in the region.

Key Details

• Transaction: Expanded distribution partnership and receipt of a new commercial order.
• Partner: Mavericks Co. Ltd., a South Korea-based health care distribution company.
• Strategic Context: The partnership follows the recent granting of a South Korean patent protecting Tempramed's proprietary thermal insulation technology.
• Market Opportunity: South Korea is identified as one of the region's fastest-growing markets for injectable therapies, with a diabetes drug sector valued at nearly $1 billion (U.S.) and projected to grow due to rising prevalence of diabetes.
• Product Focus: The partnership targets temperature-sensitive therapies including insulin, GLP-1 receptor agonists, biologics, and emergency injectables, utilizing Tempramed's passive thermal protection devices.
• Global Expansion: This deal builds on recent distribution agreements in Turkey, Israel, and Europe, reinforcing the company's global expansion strategy.
• Product Launch: The CEO noted the recent launch of the "Vivi Cap Smart" device as part of the company's smart technology platform.

Notable Quotes

• Chang Gyu An, CEO, Mavens: "Our ongoing partnership with Tempramed has demonstrated the importance of practical, everyday solutions for patients using injectable medications. This expanded agreement allows us to build on existing momentum and further integrate these solutions into South Korea's health care and pharmacy ecosystem."
• Ron Nagar, CEO, Tempramed: "This expanded partnership comes at a pivotal time for South Korea, where demand for injectable medications -- from diabetes therapies to biologics -- is rising rapidly. We look forward to fulfilling the commercial order and therefore providing our devices to the South Korean health care market... With our newly granted patent, an even stronger local presence and the recent launch of our Vivi Cap Smart device, we are better positioned than ever to ensure that patients and health care providers have access to reliable temperature protection solutions that safeguard medication quality and support better health outcomes."